New hope for advanced cancer? JMT106 injection enters first human trial
NCT ID NCT07275073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called JMT106 in 200 people with advanced solid tumors, including lung and liver cancers, who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any sign of shrinking tumors. It is a first-in-human study, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JMT106 injection
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 200 participants, so it is not yet known if JMT106 is safe or effective. Side effects may occur, and the drug may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affilicated Hospital,Zhejiang University School of Medicine
RECRUITINGZhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can your own immune cells beat advanced cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Tumor DNA mapping may unlock personalized cancer therapies
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new drug combo shrink Hard-to-Treat tumors?